Abstract |
Parainfluenza virus (PIV) can cause significant morbidity after allogeneic stem cell transplantation (SCT). We report the first use of inhaled DAS181 for PIV in an allogeneic SCT recipient. Symptoms, oxygenation, and pulmonary function tests improved. Nasopharyngeal samples showed a reduction in viral load. DAS181 should be systematically evaluated for severe PIV infection.
|
Authors | Yi-Bin Chen, Jessica P Driscoll, Steven L McAfee, Thomas R Spitzer, Eric S Rosenberg, Rebecca Sanders, Ronald B Moss, Fang Fang, Francisco M Marty |
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 53
Issue 7
Pg. e77-80
(Oct 2011)
ISSN: 1537-6591 [Electronic] United States |
PMID | 21880586
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiviral Agents
- Recombinant Fusion Proteins
- oplunofusp
- Oxygen
|
Topics |
- Administration, Inhalation
- Antiviral Agents
(administration & dosage)
- Female
- Humans
- Immunocompromised Host
- Middle Aged
- Nasopharynx
(virology)
- Oxygen
(blood)
- Parainfluenza Virus 3, Human
(isolation & purification)
- Recombinant Fusion Proteins
(administration & dosage)
- Respiratory Function Tests
- Respirovirus Infections
(diagnosis, drug therapy, pathology)
- Stem Cell Transplantation
(adverse effects)
- Transplantation, Homologous
(adverse effects)
- Treatment Outcome
- Viral Load
|